Fig. 2: Prodromal symptoms of any intensity for the most common prodromal symptoms at timepoints post-dose. | Nature Medicine

Fig. 2: Prodromal symptoms of any intensity for the most common prodromal symptoms at timepoints post-dose.

From: Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial

Fig. 2

The percentage of participants continuing to have prodromal symptoms at timepoints post-dose are shown. a–g, Participants who reported the prodromal symptoms at pre-dose: sensitivity to light (placebo, n = 273 of 449, ubrogepant 100 mg, n = 273 of 448) (a); tired, sleepy or fatigue (placebo, n = 226 of 449, ubrogepant 100 mg, n = 227 of 448) (b); neck pain or stiff neck (placebo, n = 180 of 449, ubrogepant 100 mg, n = 180 of 448) (c); sensitivity to sound (placebo, n = 162 of 449, ubrogepant 100 mg, n = 161 of 448) (d); dizziness, lightheaded, vertigo or imbalance (placebo, n = 139 of 449, ubrogepant 100 mg, n = 130 of 448) (e); difficulty concentrating (placebo, n = 101 of 449, ubrogepant 100 mg, n = 103 of 448) (f); and difficulty thinking (placebo, n = 74 of 449, ubrogepant 100 mg, n = 69 of 448) (g).

Back to article page